Search Orphan Drug Designations and Approvals
-
Generic Name: | Interleukin-3, human, recombinant |
---|---|
Date Designated: | 09/30/1993 |
Orphan Designation: | For sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma. |
Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Sandoz Pharmaceuticals Corp. 59 Route 10 East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-